ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2397

Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France

Guillaume Nardella1, Gerber Gomez2, Christian Fischer2 and Claire Monat1, 1Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, 2Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland

Meeting: ACR Convergence 2025

Keywords: Autoantibody(ies), autoimmune diseases, rheumatoid arthritis, Sjögren's syndrome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming. We evaluated the analytical performance of a multiplex microarray immunoassay (MosaiQ AiPlex® CTDplus; AliveDx, Switzerland) for the simultaneous detection of 15 autoantibodies associated with CTD, used with its fully automated proprietary platform, compared to routine methods in a reference laboratory.

Methods: A cohort of analytically characterized sera (572 reactive and 2,686 non-reactive) were included in the study. Reference methods included a multiplex bead-based immunoassay for most measurands, indirect immunofluorescence assay (IFA) for DFS70, and a chemiluminescence assay for CCP. Samples were tested with the investigational microarray immunoassay that detects IgG autoantibodies to dsDNA, SS-A 60, TRIM21 (SS-A 52), SS-B, Sm, Sm/RNP, U1RNP, Jo-1, Scl-70, CENP B, Chromatin, Ribosomal P, DFS70, RNAP III, and CCP. Performance was assessed using positive (PPA), negative (NPA) and overall percent agreement (OPA). Additionally, Cohen’s kappa coefficient was calculated.

Results: The microarray immunoassay demonstrated substantial agreement with the reference methods (overall Cohen’s kappa: 0.72), with total PPA of 86.6% (95% CI: 83.4, 89.3), total NPA of 92.3% (95% CI: 91.2, 93.3) and total OPA of 91.3%. Individual measurands showed PPA ranging from 59.1% (Sm) to 100% (TRIM21, Jo-1), and NPA ranging from 72.6% (Chromatin) to 100% (Sm, Jo-1, CCP). Notably, high kappa values for almost perfect agreement were observed for SS-A 60 (0.92), TRIM21 (0.85) Sm/RNP (0.97), and CENP B (0.87). Cohen’s kappa values for substantial agreement were observed for dsDNA (0.72), SS-B (0.75) and Sm (0.73); whereas U1RNP (0.49), Scl-70 (0.41) and Ribosomal P (0.43) showed moderated agreement. Finally, kappa values for fair agreement were found for Chromatin (0.33) and CCP (0.34). No samples were available for RNAP III and thus, no comparison was made. Due to limited sample availability, results for Jo-1 (reactive, overall) and CCP (non-reactive, overall) should be interpreted with caution. Detailed results are shown in Table 1.

Conclusion: This fully automated multiplex microarray immunoassay demonstrated overall substantial agreement with established methods for the detection of CTD-associated autoantibodies, with particularly high concordance for key targets such as SS-A 60, Sm/RNP, and CENP B. Its ability to simultaneously detect multiple autoantibodies in a single, automated run may streamline the serologic evaluation and support more efficient clinical workflows in autoimmune diagnostics.

Supporting image 1Table 1. Agreement of the Microarray Immunoassay with Comparators


Disclosures: G. Nardella: None; G. Gomez: AliveDx, 3; C. Fischer: AliveDx, 3; C. Monat: None.

To cite this abstract in AMA style:

Nardella G, Gomez G, Fischer C, Monat C. Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/analytical-performance-of-a-fully-automated-multiplexed-microarray-immunoassay-for-the-simultaneous-detection-of-fifteen-autoantibodies-associated-with-connective-tissue-diseases-in-a-reference-labora/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analytical-performance-of-a-fully-automated-multiplexed-microarray-immunoassay-for-the-simultaneous-detection-of-fifteen-autoantibodies-associated-with-connective-tissue-diseases-in-a-reference-labora/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology